Has competition helped bring down Medicare spending, while increasing quality of care and choice of plans?
Yes. As a result of the intense competition among plans offering Medicare prescription drug benefits, independent actuaries at CMS recently found that the Part D drug benefit is projected to cost less than $395 billion—nearly 40% lower than the $634 billion figure cited at the time the Medicare prescription drug plan became law in 2003.
